Immunovant (IMVT) Fundamental Analysis: Revenue, Earnings & Valuation

9.14 / 10

Outperform

Fundamental analysis rates IMVT as Outperform with a 9.1/10 score. Highlights include a high interest coverage (35.1), strong Revenue‑MV (0.52 weight) and Asset‑MV (0.92 weight). Weaknesses are high long‑term debt to working capital and a 100% current‑liabilities ratio, tempering optimism.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score3/3

Weight52.21%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.72%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-5.95%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight-22.06%

1M Return-4.96%

PB-ROE

Value4.50

Score0/3

Weight17.59%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value6.39

Score0/3

Weight-22.68%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-6.05%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.29%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-5.72%

1M Return-1.13%

Asset-MV

Value-1.80

Score3/3

Weight91.66%

1M Return11.61%

Is IMVT undervalued or overvalued?

IMVT scores 9.14/10 on fundamentals and holds a Discounted valuation at present. Backed by its -42.25% ROE, 0.00% net margin, -10.90 P/E ratio, 5.13 P/B ratio, and -1.91% earnings growth, these metrics solidify its Outperform investment rating.